Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityNo recent work listed

Hongjin Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0513-9584; OpenAlex author ID A5027655104. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

  1. Curcumin Derivative C66 Suppresses Pancreatic Cancer Progression through the Inhibition of JNK-Mediated Inflammation. Co-author DOI 10.3390/molecules27103076↗
  2. Centromere protein F is identified as a novel therapeutic target by genomics profile and contributing to the progression of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2020.10.039↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiong Chen · 1 shared paper, 2022 · strength 0.16
  2. Qinbo Chen · 1 shared paper, 2022 · strength 0.16
  3. Guang Liang · 1 shared paper, 2022 · strength 0.16
  4. Zheng Xu · 1 shared paper, 2022 · strength 0.16
  5. Hongping Xia · 1 shared paper, 2021 · strength 0.13
  6. Xiaoming Wang · 1 shared paper, 2021 · strength 0.13
  7. Xiao Mo · 1 shared paper, 2021 · strength 0.13
  8. Linhua Lan · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.